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millions. Research continues to evolve and the medical community continues to gain knowledge surrounding
the complex mechanism and pathophysiology of depletion of dopamine neurons in the substantia nigra.
Researchers continue to search for new links and possible disease-modifying therapies, as treatment options
for PD are primarily symptomatic. Serum uric acid, a powerful antioxidant, has been associated with a
decreased risk of Parkinson disease at elevated levels in several studies, indicating a possible neuroprotective
effect. Two prospective observational cohort studies established an inverse association between clinical
progression of PD and urate levels, with a slower progression noted with elevated UA levels. This systematic
review will examine whether uric acid levels can predict the clinical progression of Parkinson disease.
Methods: An exhaustive search of literature databases was conducted using Medline-OVID, CINAHL,
EBMR Multifile, and Web of Science, using the following keywords: Parkinson disease, uric acid, and disease
progression. Relevant articles were included if they were primary research evaluating uric acid levels
predicting progression of Parkinson disease. Each article was evaluated for quality using GRADE criteria.
Results: Five articles met inclusion criteria, with two studies excluded due to being secondary analyses and to
utilize the most current research. The three studies included in this systematic review are case-controlled
observational studies that compared serum uric acid levels with disease progression. All studies showed an
association between serum uric acid levels and disease progression of PD, with elevated levels being more
favorable with a slower rate of decline.
Conclusion: The results of this systematic review demonstrate the association between serum urate and the
rate of PD progression, supporting future studies exploring potential disease-modifying therapy, and
evaluating long-term risks of elevated serum urate levels.
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Abstract   
 
Background: Parkinson disease (PD) is a prevalent progressive neurodegenerative disorder, 
affecting millions. Research continues to evolve and the medical community continues to gain 
knowledge surrounding the complex mechanism and pathophysiology of depletion of dopamine 
neurons in the substantia nigra. Researchers continue to search for new links and possible 
disease-modifying therapies, as treatment options for PD are primarily symptomatic. Serum uric 
acid, a powerful antioxidant, has been associated with a decreased risk of Parkinson disease at 
elevated levels in several studies, indicating a possible neuroprotective effect. Two prospective 
observational cohort studies established an inverse association between clinical progression of 
PD and urate levels, with a slower progression noted with elevated UA levels. This systematic 
review will examine whether uric acid levels can predict the clinical progression of Parkinson 
disease. 
 
Methods: An exhaustive search of literature databases was conducted using Medline-OVID, 
CINAHL, EBMR Multifile, and Web of Science, using the following keywords: Parkinson 
disease, uric acid, and disease progression. Relevant articles were included if they were primary 
research evaluating uric acid levels predicting progression of Parkinson disease. Each article was 
evaluated for quality using GRADE criteria. 
 
Results: Five articles met inclusion criteria, with two studies excluded due to being secondary 
analyses and to utilize the most current research. The three studies included in this systematic 
review are case-controlled observational studies that compared serum uric acid levels with 
disease progression. All studies showed an association between serum uric acid levels and 
disease progression of PD, with elevated levels being more favorable with a slower rate of 
decline. 
 
Conclusion: The results of this systematic review demonstrate the association between serum 
urate and the rate of PD progression, supporting future studies exploring potential disease-
modifying therapy, and evaluating long-term risks of elevated serum urate levels. 
 
 Keywords: Parkinson disease, uric acid, urate, disease progression 
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Uric acid: a Biomarker to Predict Clinical Progression of Parkinson disease 
 
BACKGROUND 
Parkinson disease (PD) is the second most common neurodegenerative disorder, with the 
prevalence estimated to be 1% of the population over 60 years of age.1,2 PD leads to a 
progressive depletion of dopaminergic neurons in the basal ganglia, particularly in the substantia 
nigra, affecting motor control. The prevalence of people with PD over age 50 in 10 of the most 
populous countries was between 4.1 and 4.6 million in 2005, with an estimated projected 
increase between 8.7 and 9.3 million by 2030.3 Many studies also suggest the disease to be more 
common in men than women. The male predominance has been hypothesized to be due to head 
trauma, more common in males, neuroprotection from estrogen in females, pesticide exposure in 
agriculture jobs often held by males, or genetic influences of X linked genes expressed in the 
substantia nigra.2,4 
The key clinical features of a decrease in dopamine include: bradykinesia, resting tremor, 
rigidity, and impaired gait. Parkinson disease can also cause depression, anxiety, stress 
intolerance, and impaired cognition. No cure exists for Parkinson disease, but medications can 
provide symptom relief for patients. Levodopa (L-dopa), dopamine agonists, MAO-B inhibitors, 
and anticholinergic medications are most commonly used to treat the symptoms caused by PD. 
Clinical trials of new medications are focusing on neuroprotective or disease modifying 
therapies.5   
Diagnosis and progression of Parkinson disease is based on clinical impression of 
symptoms, neurologic physical examination, and patient response to dopaminergic medication. 
Currently there is no laboratory or imaging method to confirm diagnosis. Staging and 
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progression are solely clinically based, using both the comprehensive Hoehn and Yahr (H&Y) 
staging scale and Unified Parkinson Disease Rating Scale (UPDRS) to rate disability.6,7 The 
H&Y uses 5 stages to rate disability and disease progression, with a modified H&Y scale 
describing intermediate stages.6,8,9 Similarly a revised UPDRS was developed in 2007 by the 
Movement Disorder Society, which uses the combined score of non-motor and motor 
experiences of daily living, motor examination, and motor complications.7 In both clinical and 
research settings, no standard exists for determining diagnosis or disease progression. Clinical 
benchmarks for progression vary, from disease duration, H&Y stage, and UPDRS score, to time 
reaching disability sufficient enough to require dopaminergic medication, as seen in different 
research studies.10-14 
The etiology of PD still remains largely unknown, with the general consensus involving 
both genetic and environmental factors. Various hypotheses have explored the pathophysiology 
mechanism of neurodegeneration, including: genetic factors, mitochondrial dysfunction, protein 
processing abnormalities, oxidative stress, inflammation, and environmental factors.2,15 Exposure 
to pesticides, tobacco, coffee, alcohol, variation in diet, hormones, uric acid, and susceptible 
genes have all been associated with PD.2 Oxidative stress from excess free radicals and 
peroxides damage cells, a mechanism involved in aging and many disease processes. In 
autopsies of patients with PD, oxidative damage to lipids, proteins, and DNA in the substantia 
nigra was discovered and supports the evidence of oxidative stress contributing to the 
mechanism of PD.16 Clinical trials5 using antioxidants, which are substances that inhibit 
oxidation and help scavenge free radicals, have shown mixed results. Two antioxidants were 
examined in the DATATOP trial17 in 1989, with α-tocopherol (vitamin E) showing no benefit, 
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however a MAO-B inhibitor, deprenyl (selegiline) showed a delay in requiring L-dopa to help 
control motor symptoms.  
One antioxidant, urate or uric acid, has shown promise in decreasing the risk of PD in 
several studies.18-20 Uric acid (UA) is an end product of purine metabolism and has been shown 
to be a potent antioxidant by scavenging hydroxyl radicals and singlet oxygen, thereby 
decreasing oxidative stress.21 One study22 showed a decrease in both urate levels by 54% and 
dopamine levels by 85% in post-mortem substantia nigra tissue from patients with PD. This 
evidence supports the hypothesis that oxidative stress makes dopamine neurons more susceptible 
to degeneration, particularly in a low urate environment.23 Much still remains unknown about the 
link between PD and uric acid, and whether low uric acid is causative of PD or a consequence of 
the disease.   
Several studies18-20,24,25 have shown a decreased risk of developing Parkinson disease 
with elevated levels of uric acid, although this relationship may be weak or even non-existent for 
women as data differed in two studies18,25.  Similarly a history of gout or hyperuricemia has been 
associated with a decline in risk of PD, with results still inconclusive for women.26,27 After this 
association between risk of PD and urate levels was established, two groups conducted 
prospective observational cohort studies10,14 using participants enrolled in larger randomized 
control trials (RCTs). Both studies10,14 showed similar results with the overall trend showing a 
decrease in the progression of Parkinson disease with patients that have higher levels of uric 
acid. In the Schwarzschild et al study14, subjects in the highest serum urate quintile reached the 
primary clinical endpoint at half of the rate of the lowest serum urate quintile (HR=0.51; 95% 
CI: 0.37 to 0.72; p=0.0002). Ascherio et al10 demonstrated a 36% reduction in reaching the 
primary endpoint of requiring levodopa therapy (HR=0.64; 95% CI 0.44 to 0.94; p=0.002), 
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compared to the lowest serum urate quintile. While there are several limitations with secondary 
analyses, both were able to test an unforeseen hypothesis to help lay the groundwork in 
suggesting an inverse correlation between serum UA levels and disease of progression of PD. 
The focus of this systematic review is to examine recent studies involving serum urate 
levels and clinical progression, a link made possible by the results shown in two prospective 
observational cohort studies10,14 first pointing to a trend of slowed PD progression with elevated 
UA levels. With the majority of research pointing to as association between uric acid levels and 
Parkinson disease, the next clinical question is: can uric acid levels predict the progression of 
Parkinson disease? 
METHODS 
An exhaustive search of available literature databases was conducted using Medline-
OVID, CINAHL, EBMR Multifile, and Web of Science. Keywords used included: Parkinson 
disease, uric acid, and disease progression. Eligibility criteria included studies which were 
primary research articles evaluating uric acid levels predicting clinical progression of Parkinson 
disease, conducted on humans, and in the English language. References of studies and other 
related articles were searched for further sources. The included articles were evaluated for 
quality using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE).32 
RESULTS 
The initial results of the search yielded 60 articles for review. Three articles met 
eligibility criteria. Two prospective observational cohort studies10,14 were excluded from this 
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systematic review, due to being secondary analyses. This allows for focus on the most current 
data. These two excluded articles, 10,14 as previously discussed, did however show significant 
results to help establish this association. Three case controlled observational studies11-13 were 
evaluated for quality and included in this systematic review.  See table 1 for GRADE analysis.  
Summary of findings are presented in Tables II-IV. 
Andreadou et al 
In 2009, Andreadou et al11 conducted a case-controlled observational study examining 
the relationship between serum UA levels of 43 PD patients and 47 age and gender matched 
controls. The outcomes assessed in the study included: H&Y stage, disease duration in months, 
UPDRS part III score, and daily dose of levodopa. Enrollment criteria for patients with PD was 
diagnosis based on the UKPD Society Brain Bank, 33 with exclusion criteria being the use of uric 
acid lowering agents or diuretic use. Controls were selected if they were healthy, excluded if 
they had a family history of PD or an abnormal neurologic exam.11   
Participants in the PD group were separated into subgroups of those treated with anti-PD 
medication (n=22) and those untreated (n=21); all were assess using H&Y stage scale and 
UPDRS part III to determine disease progression. All participants enrolled in the study 
underwent a controlled diet for 5 days prior to collection of blood samples. No follow up was 
conducted, as observations were made from group data, not individual progression of PD.11 
Lower serum UA levels were found in the PD group, both treated and untreated, 
compared to the control group (p=0.009). This finding was slightly less significant when analysis 
was separated into each sex, however it still remained significant for both men and women. 
Possible confounders were analyzed showing only significance in gender contributing to serum 
UA levels, but no significance in age or BMI.11   
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The Andreadou et al study demonstrated Hoehn & Yahr stages inversely associated with 
serum urate levels, with higher serum UA in stage 2, compared to stage 2.5 (p=0.01), and stage 3 
(p=0.003). Interestingly, they did not find a significant effect of UPDRS scores and serum UA 
concentrations for either men or women (All PD patients p=0.15; men Rs= 0.078, p=0.73; 
women Rs= 0.109, p=0.637). Serum UA concentrations were noted to be inversely correlated for 
both disease duration and daily levodopa dose in both men and women (Table IV shows All PD 
patients Rs= -0.397, p=0.009; men Rs= -0.441, p=0.04; women Rs= -0.221, p=0.337) and daily 
levodopa dose (All PD patients: Rp= -0.498, p=0.026; Men Rs= -0.717, p=0.03; women Rs= -
0.17, p=0.966).11 
The authors concluded that the relationship between urate and PD should be further 
explored with altering serum UA levels in future clinical trials, in hopes that increasing urate 
levels will have a neuroprotective effect. They also discuss future research to clarify conflicting 
data differences between men and women, theorizing PD pathophysiology, diet preferences, age 
onset, and hormonal influence on serum UA levels may be contributing to variations between 
men and women. Small sample size was the limitation mentioned by the investigators, possibly 
negatively influencing precision of data.11 
Ikeda et al 
Ikeda et al12 conducted an observational cohort study in 2011 comparing urate, 
paroxonase-1 (PON1), iron, ferritin, and lipid serum levels in Japanese PD patients and controls. 
The study12 enrolled a total of 119 patients with PD (n=56 men, n=63 women), diagnosed using 
the UKPD Society Brain Bank criteria.33 Disease progression was evaluated by Hoehn and Yahr 
stage and disease duration. Controls were matched to the PD group based on sex, age, and BMI. 
Exclusion criteria included: support with ambulation, use of diuretics, urate- or cholesterol-
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lowering medications, iron supplementation, or the presence of gastrectomy or gastrostomy, 
requiring tube feedings. Samples analyzed were drawn from fasting study participants, 
measuring total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C), serum iron, 
serum ferritin, and paraoxon. LDL cholesterol (LDL-C) was calculated by using the Friedewald 
formula (LDL-C (mg/dl)=TC (mg/dl) – HDL-C (mg/dl) – 0.2 X TG (mg/dl)). No follow up was 
discussed in this study. The PON1 levels were measured indirectly by using a paraoxon serum 
measurement, calculating the paraoxonase activity. Paraoxonase-1 is a type of high-density 
lipoprotein (HDL) bound enzymes that has shown to have antioxidant effects.12   
Serum levels of TC, LDL-C, urate, and PON1 activity were substantially decreased in 
both female and male PD patients (p<0.01), compared to their matched controls. An increase in 
serum ferritin levels were noted in both male and female patients, compared to controls (p<0.05). 
No significance difference resulted in comparison of HDL-C and TG levels of PD patients and 
controls.12  
Results for serum urate demonstrated a decrease in disease progression measured by Yahr 
stage (Men: Rs=-0.38, p<0.01; Women Rs= -0.36, p<0.01) and disease duration in years (Men: 
Rs= -0.39, p<0.01; Women: Rs= -0.30, p<0.05) for both men and women, respectively. The 
authors also discovered a similar inverse relationship between serum PON1 activity and both 
Yahr stage and PD duration in both genders. The authors did not discover any relationships 
between the patient daily dose of L-dopa and the serological data.12   
The investigators found limitations in this study, with lack of prospective study design 
and lack of diet control methodology of participants. They discussed the link they found between 
the serological data collected, and disease progression of PD, suggesting the use of these 
biomarkers to monitor disease progression.12 
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Sun et al 
 
In this observational cohort study13 performed in 2012, Sun et al researched serum UA 
levels in Chinese patients with PD, compared to age and gender matched controls. The 
investigators assessed PD progression by two outcomes of disease duration and H&Y staging. 
They also measured the concentration of serum creatinine to exclude the possibility that renal 
excretion of SCr affects serum UA levels.13 
A total of 411 patients diagnosed with PD at the First Affiliated Hospital of Sun Yat-sen 
University in China, were enrolled in this study. Diagnosis was in concordance with the clinical 
criteria of the UKPD Society Brain Bank33 and assessed clinically based on the Hoehn and Yahr 
staging scale6. Age and gender matched controls were excluded if they had a history of chronic 
disease, used medications possibly affecting serum uric acid levels, history of smoking or 
alcohol consumption, family history of PD, or if they had an abnormal neurologic exam. The 
authors divided the PD group into H&Y stage subgroups, early stage (H&Y1.0-1.5), middle 
stage (H&Y 2.0-2.5), and late stage (H&Y ≥3.0). No medications used were discussed in any PD 
group. Diet was controlled and managed for two weeks prior to samples being drawn. Two 
fasting blood sample were drawn two weeks apart, with diet managed for two weeks prior to the 
study. Since the authors did not find much difference between the values of the two draws, the 
average value was used in statistical analysis. No follow up was discussed in this study, thus 
progression was not observed to change over time.13  
Hoehn & Yahr stages were inversely associated with serum uric acid levels, with p values 
significant for both male and female respectively (male Rs= -0.360, p<0.01; female Rs= -0.516, 
p<0.01). Likewise results of disease duration demonstrated an inverse correlation between serum 
UA levels for both sexes (male Rs= -0.290, p<0.01; female Rs= -0.272, p<0.01). Comparison of 
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serum creatinine (SCr) concentrations between the control group and PD group exhibited no 
significant difference, however both serum UA and SCr were lower in women than men in both 
groups. Subgroups analyzed resulted in late stage PD with significantly lower UA levels 
compared to both middle and early stage groups (p<0.01).13   
Sun et al13 investigators verified results of lower serum UA levels in PD patients among a 
Chinese population. They discussed the inverse association of serum urate levels with both 
disease duration and H&Y staging scale, which suggest a neuroprotective role of serum UA. 
Limitations considered by the authors included: not using UPDRS scores and not exploring 
possible interactions between dopaminergic therapy and serum UA, both of which would 
strengthen the observations of this study. They suggest the results point to a potential therapy 
application of increasing serum UA, since it is suggested that low serum UA levels may both 
increase risk of PD and possibly acceleration of disease progression.13 
DISCUSSION 
Measuring serum urate levels in patients with Parkinson disease may be used in the future 
to determine the progression of the disease. The majority of research may point to an association 
between elevated serum urate levels and a slower rate of PD progression, as seen in the three 
studies included in this systematic review.11-13 The result summaries presented in Tables II-IV 
justify the continuation of research in this field to understand the significance between uric acid 
and PD. Currently there is not enough quality data to suggest using serum UA levels in the 
clinical setting. Higher quality studies are needed to further demonstrate this association and to 
determine how urate can be used as a biomarker for the progression of PD. The results from 
these three studies, 11-13 and the two larger prospective cohort studies10,14 do warrant a future 
clinical trial using urate as a potential neuroprotective or disease-modifying medication. Much 
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still remains unknown regarding the mechanism of dopamine neuron degeneration in PD; 
therefore when a correlation is discovered, it is the duty of the research community to further 
investigate.  
Overall all three studies11-13 demonstrated an inverse relationship between uric acid levels 
and disease duration; the longer a patient has had PD, the lower the levels of serum urate. Two 
studies found this association to be significant in both men (p<0.01 and p<0.01) and women 
(p<0.05 and p<0.01) respectively.12,13 Andreadou et al did not find a significant correlation with 
women (p=0.0337), but did with men (p=0.04); however this data is limited due to the low 
number of study participants.11 The Hoehn and Yahr stage correlated to serum UA levels in both 
Ikeda et al and Sun et al studies, for both men and women.12 The third study demonstrated that 
H&Y stage 2 had a higher mean serum UA level compared to stage 2.5 (p=0.001), and compared 
to stage 3 (p=0.003).11 This study did not present their data with spearman coefficients and did 
not gender stratify H&Y outcome results to distinguish any differences between men and 
women.11 The outcome of change in UPDRS score was only used in one of the included studies, 
and was not significantly affected by serum UA levels (Rs=0.078, p=0.73 for male and Rs=0.109, 
p=0.637 for female).11 The studies Sun et al and Ikeda et al would both have a higher quality of 
data if they would have also used the comprehensive UPDRS scale of motor and non-motor 
findings, as a measure of disease progression.12,13 
One of the inherent challenges of studying PD progression and designing a study, lie in 
the fact that diagnosis and staging are largely a subjective determination by clinicians. No 
standard exists clinically or in research to measure disease progression or staging. This 
inconsistency was demonstrated in the studies included in this systematic review, as each 
differed in methodology of determining PD progression and clinical outcomes. All three of the 
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studies11-13 included showed methodological weakness through subjective measurement of 
disease duration, resulting in a quality downgrade to “very low”, as shown in Table I. This 
supports the potential for detection bias, with variations in clinical judgment of diagnosis of 
Parkinson disease to measure how long a participant has had the disease. A tremor may initially 
be misdiagnosed as essential tremor, making it possible that patients are not diagnosed with PD 
the same time of symptom onset. Using H&Y scale and change in UPDRS scale are more 
objective measures of PD progression. Sun et al discussed using the UPDRS scale would have 
increased the quality of data, by using a more comprehensive measure of both motor and non-
motor findings in PD.13 A higher level of credibility would be given if investigators described in 
the methodology how clinicians made the determination of clinical endpoints. A standard for 
diagnosis and following progression should be established for clinical trials and in the clinical 
setting, particularly for more subjective outcomes. 
Another major limitation resulting in downgrading of two studies was small sample size, 
leading to possible imprecision of results and overestimate of the significance of findings.11,12 
Serum urate levels were compared to a point in time of a patient’s clinical stage for all three 
studies,11-13 compiling data with no follow up completed.  In future studies it would be beneficial 
to follow disease progression over time to determine if an individual’s rate of progression 
corresponds to serum urate levels.  
Other limitations that do not necessarily warrant quality downgrading, but must be taken 
into consideration are possible confounding factors.  Diet, age, gender, levodopa dose, BMI, 
serum creatinine levels, and other medications have the potential to influence serum urate levels. 
Two studies11,13 included in the systematic review controlled diet prior to sample collection; 
however, one study12 did not control diet or obtain self-reported information about diet for PD 
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patients or controls. Sun et al did not evaluate dose of dopaminergic medication and its effect on 
serum UA.13 One research study34 showed a significant association between the daily dose of 
levodopa and urine uric acid levels; another study11 found this correlation only to be found in 
men. 
Lower mean levels of serum urate have been associated in women, compared to men. 
Research has continued to show conflicting associations between urate and PD progression of 
men and women, which several study results demonstrate significant for men only.10,11,14 There 
are many suggested theories for this gender difference, small study population of women in 
studies,10,14 lower percentage of women represented in higher serum urate quintiles,10 biological 
effect of gender on disease, and estrogen influencing renal excretion of urate.35 Much remains 
unknown regarding the mechanism of dopamine neuron degeneration in PD, the complexity 
increasing with possible differences in gender. Future studies are needed to clarify the difference 
in gender and its potential application to variations in treatment therapy between male and 
female patients with PD. 
The next step to assess the relationship between uric acid and PD is to conduct a larger 
scale, long-term, randomized control trial using urate as a therapy to increase serum urate levels 
and to assess the impact on progression of Parkinson disease. With observational studies it is 
challenging to perform blinding, especially with studying disease progression, thus using an RCT 
would provide higher quality of evidence. Future studies should use subgroups of PD patients 
treated with levodopa and untreated, stratifying results by gender, and evaluating progression 
with UPDRS scale, H&Y scale, daily dose of levodopa, and in untreated patients measuring time 
until the participant reaches disability sufficient enough to begin levodopa therapy. A study36 has 
already been performed to evaluate the safety of increasing serum urate levels, which is the first 
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step required before a large scale RCT was conducted. Some research shows evidence for 
increased cardiovascular events and other adverse effects of elevated urate levels.30-32 A long-
term study is necessary to determine if benefits from the medication would outweigh any 
increased cardiovascular risks that may result.28-30 
In 2014 the Parkinson Study Group SURE-PD published data from the randomized 
control trial36 of 75 participants, investigating the safety, tolerability, and efficacy of inosine, a 
urate precursor, to elevate serum and CSF urate concentrations. Results showed that serious side 
effects, such as cardiovascular events are lower or similar in the inosine group compared to 
placebo. Three patients experienced urolithiasis, one confirmed uric acid stone and no participant 
experienced gout while using the medication. No adverse event resulted in participant 
withdrawal and at 6 months of therapy, 95% of participants tolerated inosine. Inosine was 
efficacious at elevating serum urate levels, 2.3 and 3.0mg/dL respectively in both inosine groups 
(p<0.01) vs the placebo group. CSF was also higher in the both inosine groups (p=.006 and 
p<0.001) than placebo, indicating inosine crosses the blood brain barrier. This study performed a 
primary analysis with findings supporting use of inosine as a possible disease-modifying agent, 
hopeful in slowing the progression of PD.36   
CONCLUSION 
There still is not enough high quality data available to support clinicians measuring 
serum UA levels routinely among patients with Parkinson disease to determine progression or 
diagnosis. All three studies showed an inverse association between serum urate and rate of 
clinical progression of Parkinson disease, differing primarily in outcomes measuring disease 
progression and significance of findings with gender. Although the prospective cohort studies 
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that helped establish this correlation between PD progression and urate were of higher quality 
due to their larger size, the three studies echoed their results and support future research. The 
evidence found in studies measuring serum UA levels and PD progression in this systematic 
review, along with the recent Parkinson Study Group SURE PD trial, warrant a future clinical 
trial using inosine as a possible disease-modifying treatment. Long-term use of elevated serum 
urate levels must determine if a potential benefit is worth any adverse events.  
While future research is required, the trend continues toward urate being a promising 
treatment option, possibly slowing the rate of decline in PD, and may be considered a biomarker 
for the progression and management of the disease. With so many unknown factors contributing 
to Parkinson disease, the hope and goal of the medical community is to one day discover 
treatment options to delay the progression of the disease.  
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Table I. GRADE assessment  
 
 
 
 Table II.  Summary of findings Andreadou et al11 
Outcome Correlation to serum UA levels Men (n=22) Women (n=21) Total PD (n=43 
Disease 
Duration 
(months) 
Spearman 
coeffieient (Rs) -0.441 -0.221 -0.397 
P value 0.04 0.337 0.009 
Daily 
levodopa 
dose (mg) 
Spearman 
coeffieient (Rs) -0.717 -0.17 Rp= -0.498 
P value 0.03 0.966 0.026 
 
Table III.  Summary of finding Ikeda et al12 
Outcome Correlation to serum UA levels Men (n=56) Women (n=63) 
H&Y 
Stage 
Spearman 
coeffieient (Rs) -0.38 -0.36 
P value <0.01 <0.01 
Disease 
Duration 
(years) 
Spearman 
coeffieient (Rs) -0.39 -0.30 
P value <0.01 <0.05 
 
Table IV.  Summary of findings Sun et al13 
Outcome Correlation to serum UA levels Men (n=207) Women (n=204) Total (n=411) 
H&Y 
Stage 
Spearman 
coeffieient (Rs) -0.360 -0.516 -0.429 
P value <0.01 <0.01 <0.01 
Disease 
Duration 
(years) 
Spearman 
coeffieient (Rs) -0.290 -0.272 -0.284 
P value <0.01 <0.01 <0.01 
 
 
Quality Assessment  
  Downgrade Criteria 
Quality  
Design Outcome Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Andreadou 
et al Observational
 
Change in UPDRS 
score Not Serious Not serious Serious
b Not serious No 
Very low 
H&Y Stage Not Serious Not serious Seriousb Not serious No 
Disease Duration 
(Months) Serious
a Not serious Seriousb Not serious No 
Levodopa dose (mg) Not Serious Not serious Seriousb Not serious No 
Ikeda et al 
Observational 
H&Y Stage  Not Serious Not Serious   Seriousb Not Serious No 
Very low Disease Duration 
(Years) Serious
a  Not Serious Seriousb Not Serious No 
Sun et al 
Observational 
H&Y Stage  Not serious  Not serious Not serious Not serious No 
Very low Disease Duration 
(Years) Serious
a Not serious Not serious Not serious No 
a: subjective determination of disease duration (possible detection bias) 
b: small sample size 
